Regeneron Pharmaceuticals (NASDAQ:REGN) and Clovis Oncology (NASDAQ:CLVS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.
Profitability
This table compares Regeneron Pharmaceuticals and Clovis Oncology's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Regeneron Pharmaceuticals | 38.28% | 28.97% | 20.11% |
Clovis Oncology | -230.34% | N/A | -57.56% |
Earnings and Valuation
This table compares Regeneron Pharmaceuticals and Clovis Oncology's top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Regeneron Pharmaceuticals | $7.86 billion | 6.47 | $2.12 billion | $21.47 | 22.13 |
Clovis Oncology | $143.01 million | 4.55 | $-400,420,000.00 | ($7.60) | -0.82 |
Regeneron Pharmaceuticals has higher revenue and earnings than Clovis Oncology. Clovis Oncology is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 57.8% of Clovis Oncology shares are held by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are held by company insiders. Comparatively, 6.6% of Clovis Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Analyst Recommendations
This is a breakdown of current recommendations for Regeneron Pharmaceuticals and Clovis Oncology, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Regeneron Pharmaceuticals | 0 | 5 | 14 | 1 | 2.80 |
Clovis Oncology | 2 | 2 | 2 | 0 | 2.00 |
Regeneron Pharmaceuticals presently has a consensus price target of $637.2083, suggesting a potential upside of 34.10%. Clovis Oncology has a consensus price target of $9.50, suggesting a potential upside of 52.49%. Given Clovis Oncology's higher probable upside, analysts plainly believe Clovis Oncology is more favorable than Regeneron Pharmaceuticals.
Volatility & Risk
Regeneron Pharmaceuticals has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500. Comparatively, Clovis Oncology has a beta of 2.1, suggesting that its stock price is 110% more volatile than the S&P 500.
Summary
Regeneron Pharmaceuticals beats Clovis Oncology on 13 of the 15 factors compared between the two stocks.